What is Palonosetron Accord used for?

Palonosetron Accord

Active Ingredient:: Palonosetron
Origin:: EU

Palonosetron Accord (Palonosetron)

Palonosetron, the active ingredient in Palonosetron Accord, is a 5-HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH India supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH India supplies Palonosetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palonosetron Accord is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways related to cancer therapy and surgery.

Chemotherapy‑induced nausea and vomiting (CINV): helps prevent acute and delayed episodes in patients receiving highly emetogenic chemotherapy.
Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia.
Radiotherapy‑induced nausea and vomiting: mitigates nausea associated with abdominal or pelvic radiation treatments.
Anticipatory nausea and vomiting: lessens nausea that patients may experience before chemotherapy based on prior experiences.

How It Works

Palonosetron binds with high affinity to the 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and the central nervous system. By blocking serotonin from activating these receptors, it interrupts the signaling cascade that triggers the vomiting reflex, providing prolonged anti‑emetic protection that can extend beyond 24 hours after a single dose.

Side Effects

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects

Headache: mild to moderate intensity.
Constipation: reduced bowel movements.
Fatigue: feeling of tiredness.
Diarrhoea: loose stools.
Dizziness: light‑headed sensation.

Serious or Rare Side Effects

QT interval prolongation: cardiac rhythm changes detectable on ECG.
Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
Serotonin syndrome: agitation, fever, tremor when combined with serotonergic agents.
Cardiac arrhythmias: irregular heartbeats beyond QT changes.
Neuro‑muscular weakness: rare muscle tone alterations.

Precautions & Warnings

When prescribing Palonosetron Accord, clinicians should consider several safety aspects.

Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk.
Concomitant serotonergic drugs: evaluate for potential serotonin syndrome.
Renal impairment: adjust considerations for patients with severe kidney dysfunction.
Hepatic impairment: use caution in patients with liver disease.
Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Palonosetron may interact with other medications, requiring attention to the following categories.

Major Interactions (Avoid)

QT‑prolonging agents: concurrent use may increase risk of cardiac arrhythmias.
Potent CYP3A4 inhibitors: may raise palonosetron plasma levels.

Moderate Interactions (Monitor Closely)

Serotonergic antidepressants (SSRIs, SNRIs): monitor for signs of serotonin syndrome.
Anticholinergic drugs: may enhance constipation.
Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.
Antifungal azoles: potential modest increase in exposure.
Opioid analgesics: may compound central nervous system depression.

Frequently Asked Questions

Palonosetron Accord is an oral anti‑emetic medication that is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. It belongs to the 5‑HT3 receptor antagonist class and is indicated for adult patients who require protection against both acute and delayed emesis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.